{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Progressive&page=35",
    "query": {
      "intervention": "Progressive",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 2387,
    "total_pages": 239,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Progressive&page=36&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Progressive&page=34&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T15:11:43.420Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01401842",
      "title": "Reduction of Risk for Low Back Injury in Theater of Operations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lower Back Injury"
      ],
      "interventions": [
        {
          "name": "Lumbar ext. high intensity progressive resistance exercise",
          "type": "OTHER"
        },
        {
          "name": "Low intensity core stabilization exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 582,
      "start_date": "2012-06",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2015-05-25",
      "last_synced_at": "2026-10-27T15:11:43.420Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Fort Sam Houston, Texas",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01401842"
    },
    {
      "nct_id": "NCT01688401",
      "title": "Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma (DIPG)"
      ],
      "interventions": [
        {
          "name": "Melphalan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Month to 17 Years"
      },
      "enrollment_count": 3,
      "start_date": "2013-03-08",
      "completion_date": "2018-11-26",
      "has_results": false,
      "last_update_posted_date": "2019-03-28",
      "last_synced_at": "2026-10-27T15:11:43.420Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01688401"
    },
    {
      "nct_id": "NCT03058965",
      "title": "Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Healthy Volunteers",
        "Progressive Supranuclear Palsy"
      ],
      "interventions": [
        {
          "name": "[18F]MNI-958",
          "type": "DRUG"
        },
        {
          "name": "[18F]Florbetapir",
          "type": "DRUG"
        },
        {
          "name": "DaTscan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular NeuroImaging",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-11-29",
      "completion_date": "2018-05-11",
      "has_results": false,
      "last_update_posted_date": "2019-03-25",
      "last_synced_at": "2026-10-27T15:11:43.420Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03058965"
    },
    {
      "nct_id": "NCT04246177",
      "title": "Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        },
        {
          "name": "IV Placebo",
          "type": "DRUG"
        },
        {
          "name": "TACE",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2020-05-22",
      "completion_date": "2026-03-26",
      "has_results": true,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-27T15:11:43.420Z",
      "location_count": 27,
      "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 22 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04246177"
    },
    {
      "nct_id": "NCT06679101",
      "title": "A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Newly Diagnosed Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Belantamab mafodotin",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": "2024-12-16",
      "completion_date": "2031-04-28",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-27T15:11:43.420Z",
      "location_count": 30,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 26 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06679101"
    },
    {
      "nct_id": "NCT06261528",
      "title": "Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Light therapy",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-04-18",
      "completion_date": "2026-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-10-27T15:11:43.420Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06261528"
    },
    {
      "nct_id": "NCT07013565",
      "title": "Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic Large Cell Lymphoma, ALK-Positive"
      ],
      "interventions": [
        {
          "name": "Vinblastine (Velban)",
          "type": "DRUG"
        },
        {
          "name": "Brentuximab vedotin (Adcetris)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab (Opdivo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "1 Year to 39 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-08-07",
      "completion_date": "2030-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-10-27T15:11:43.420Z",
      "location_count": 1,
      "location_summary": "Valhalla, New York",
      "locations": [
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07013565"
    },
    {
      "nct_id": "NCT04907539",
      "title": "A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "RXC004",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Denosumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Redx Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-11-08",
      "completion_date": "2024-04-02",
      "has_results": true,
      "last_update_posted_date": "2025-04-16",
      "last_synced_at": "2026-10-27T15:11:43.420Z",
      "location_count": 5,
      "location_summary": "Santa Rosa, California • Indianapolis, Indiana • Las Vegas, Nevada + 2 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Kingswood",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04907539"
    },
    {
      "nct_id": "NCT03636477",
      "title": "A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Ad-RTS-hIL-12",
          "type": "BIOLOGICAL"
        },
        {
          "name": "veledimex",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Alaunos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-06-18",
      "completion_date": "2021-06-30",
      "has_results": true,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-27T15:11:43.420Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03636477"
    },
    {
      "nct_id": "NCT04608812",
      "title": "Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioma, Malignant",
        "High Grade Glioma",
        "Glioblastoma",
        "Glioblastoma Multiforme",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "OS2966",
          "type": "DRUG"
        },
        {
          "name": "Gadoteridol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoSynergy, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2021-03-02",
      "completion_date": "2023-02-27",
      "has_results": false,
      "last_update_posted_date": "2023-08-18",
      "last_synced_at": "2026-10-27T15:11:43.420Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04608812"
    }
  ]
}